Zavante Therapeutics Forms Scientific Advisory Board and Appoints Infectious Disease Experts as Members

8/31/2016

Scientific Advisory Board members to support pre-clinical, microbiology and clinical development programs for lead product candidate ZTI-01

SAN DIEGO, CA – August 31, 2016 – Zavante, Therapeutics, Inc., a privately-held, late clinical-stage biopharmaceutical company, today announced that it has formed a Scientific Advisory Board and has appointed eight infectious disease specialists to serve as strategic and scientific resources to the Company.  ZTI-01 (fosfomycin for injection) is an investigational antibiotic under development for the treatment of hospitalized patients with complicated urinary tract infections (cUTI), including acute pyelonephritis.

“We are pleased to bring together this strong team of infectious disease specialists to support the development efforts of ZTI-01, our lead product candidate,” said Ted Schroeder, chief executive officer of Zavante. “We believe ZTI-01, a first-in-class injectable antibiotic, will provide additional treatment options in the hospital setting where current therapeutic choices are severely limited.”

Inaugural members of the Zavante Scientific Advisory Board:

  • Paul G. Ambrose, Pharm. D., F.I.D.S.A.
  • John S. Bradley, M.D., F.A.A.P., F.I.D.S.A.
  • George L. Drusano, M.D.
  • Ronald N. Jones, M.D.
  • Keith Rodvold, Pharm.D.
  • Albert T. Sheldon, Ph.D.
  • Andrew Shorr, M.D., M.P.H.
  • Robert K. Flamm, Ph.D.

For a full biography of each advisory board member, please visit www.zavante.com/SAB

Zavante’s ZTI-01, is a first-in-class injectable antibiotic that has demonstrated a broad spectrum of bactericidal Gram-negative and Gram-positive activity in vitro, including activity against most contemporary multi-drug resistant (MDR) strains.

FDA granted Fast Track designation and Qualified Infectious Disease Product (QIDP) designation for the investigation of ZTI-01 for the following indications:

  • cUTI
  • Hospital-Acquired Bacterial Pneumonia (HABP)
  • Ventilator-Associated Bacterial Pneumonia (VABP)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Complicated Intra-Abdominal Infections (cIAI)

In July 2016, the first patient was randomized in the ZEUS (ZTI-01 Efficacy and Safety) study.  ZEUS is the pivotal study intended to support a New Drug Application for ZTI-01 in the U.S. The study is titled “Multi-center, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 vs. piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults.” More clinical trial information is available at www.clinicaltrials.gov.

The Company expects to complete enrollment in the ZEUS study in the first half of 2017.

About Zavante Therapeutics, Inc.

Zavante Therapeutics, Inc. is a privately-held, late clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Additional information is available at www.zavante.com.

Investor Contact:
Kevin Finney
Zavante Therapeutics
kfinney@zavante.com
858-299-4990

Media Contact:
Amy Caterina
Zavante Therapeutics
acaterina@zavante.com
619-379-0054